Medapia

Entacapone, the active ingredient in Medapia, is a catechol-O-methyltransferase (COMT) inhibitor presented as a tablet for oral use. It is used as adjunct therapy with levodopa/carbidopa in Parkinson's disease to improve motor control.

GNH USA supplies Medapia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. It is authorized for prescription use in the European Union and conforms to EU pharmacopeial standards. The product undergoes rigorous quality control and is packaged in moisture‑protected blister packs to maintain stability.

Entacapone is used as an adjunct in the management of Parkinson's disease, a neurodegenerative disorder affecting dopaminergic pathways.

- Parkinson's disease (as adjunct to levodopa/carbidopa): Enhances and prolongs the effect of levodopa, reducing motor fluctuations. - Motor fluctuations in Parkinson's disease: Improves on/off periods and stabilises symptom control. - Advanced Parkinson's disease requiring dose optimisation: Supports more consistent dopamine availability, allowing lower levodopa dosing.

Entacapone may cause a range of adverse reactions, from mild to serious. Patients should be informed of common and rare events.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, usually transient. - Abdominal pain: discomfort in the stomach area. - Dyskinesia: involuntary movements, often related to levodopa. - Urine discoloration: brownish hue, harmless. - Dizziness: light‑headed sensation, especially on standing.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes, requires immediate medical attention. - Agranulocytosis: marked reduction in white blood cells, risk of infection. - Severe allergic reactions: rash, swelling, anaphylaxis. - Neuroleptic malignant syndrome: high fever, muscle rigidity, medical emergency. - Hematologic abnormalities: thrombocytopenia, anemia. - Cardiac arrhythmias: irregular heartbeat in susceptible individuals.

When prescribing Entacapone, clinicians should consider several safety aspects. - Renal impairment: assess kidney function and adjust therapy if needed. - Hepatic impairment: monitor liver enzymes regularly. - History of hypersensitivity: avoid use in patients with known allergy to Entacapone. - Concomitant MAO‑B inhibitors: avoid due to risk of hypertensive crisis. - Pregnancy Category B: use only when the potential benefit justifies the potential risk. - Store at ambient temperature: keep in the original pack, protect from moisture.

Entacapone can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may precipitate hypertensive crisis. - Ipecac syrup: can increase toxicity of Entacapone. - Certain antihypertensives (e.g., clonidine): risk of excessive blood pressure drop.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance hypotensive effect, monitor blood pressure. - Dopamine agonists: may increase dyskinesia, adjust levodopa dose as needed. - SSRIs or SNRIs: watch for additive serotonergic effects, though risk is low.